Gastroenterology News

A pressing question on the mind of any practice owner when selling his or her practice is “how much money will I get?”

The FDA has approved Takeda Pharmaceuticals’ Eohilia as the “first and only oral therapy” for treatment of eosinophilic esophagitis in patients aged 11 years or older, according to a press release.

The term “wellness” has become increasingly popular in the general public at large, and within the medical community specifically.

Researchers reported low perioperative risk for complications among patients who underwent sleeve gastrectomy or Roux-en-Y gastric bypass, with no clinically significant difference between groups, according to a study in JAMA Network Open.

A $37 million study led by Newcastle University, University of Edinburgh and Boehringer Ingelheim is underway to address the “urgent need” for anti-scarring therapies for individuals with liver disease.

A lot can change in a year. But has it?

Use of a second anti-tumor necrosis factor agent resulted in early clinical response in nearly 50% of patients with ulcerative colitis and long-term remission in about 30%, with no difference reported between IV and subcutaneous agents.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.